ClinicalTrials.gg
RecruitingNCT07110584Updated Mar 5, 2026

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

A Phase 1/2 interventional study of MDX2004 in Advanced Tumors, sponsored by ModeX Therapeutics, An OPKO Health Company. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by ModeX Therapeutics, An OPKO Health Company (part of OPKO Health, Inc.) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
235
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.

02

Conditions studied

  • Advanced Tumors
03

In context

Lead sponsor

ModeX Therapeutics, An OPKO Health Company is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

First submitted after ModeX Therapeutics became part of OPKO Health, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years of age.
  • or cytologically confirmed diagnosis of locally advanced or .
  • (ECOG) performance status of 0 or 1.
  • All participants should have at least 1 measurable site of disease according to v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.
  • Adequate hematologic, hepatic and renal function.
  • All use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Any cardiac disease.
  • Unresolved toxicities from previous anticancer therapy.
  • Known untreated, active, or uncontrolled .
  • Previous Grade 3 or 4 immune-related toxicity that led to the discontinuation of treatment, within 6 months prior to the first dose of MDX2004.
  • Active medical condition requiring chronic systemic use (>10 mg/day prednisone or equivalent) or therapy, within 6 months prior to the first dose of MDX2004.
  • Known positivity with (HIV), known active or C, or uncontrolled chronic or ongoing infection requiring intravenous treatment.
  • Prior solid organ or hematologic transplant
  • Require supplemental oxygen for activities of daily living
  • Participant is not suitable for participation, whatever the reason, as judged by the Investigator including medical or clinical conditions.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
235 participants (estimated)

Study arms

  • Experimental
    Dose Escalation - Part A

    Participants with advanced tumors will receive MDX2004 as intravenous (IV) infusion.

    Drug: MDX2004

  • Experimental
    Indication Optimization - Part B

    Participants with select advanced tumors will receive MDX2004 as intravenous (IV) infusion.

    Drug: MDX2004

  • Experimental
    Dose Optimization - Part C

    Participants with select advanced tumors will receive one of two recommended doses of MDX2004 as intravenous (IV) infusion.

    Drug: MDX2004

  • Experimental
    Dose Expansion - Part D

    Participants with select advanced tumors will receive the recommended Phase 2 dose of MDX2004 as intravenous (IV) infusion.

    Drug: MDX2004

Interventions

  • DrugMDX2004

    MDX2004 intravenous infusion

06

What researchers measure

Primary outcomes

  1. All Study Parts: Adverse Events (AEs)

    Incidence and severity of adverse events (AEs) and serious AEs (SAEs), including changes in clinical laboratory parameters, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading criteria, including changes in clinical laboratory parameters

    Time frame: Baseline until 90 days after the participant has the last dose of MDX2004

  2. Part A only - Maximum Tolerated Dose (MTD) or Recommended Phase 2 dose (RP2D)

    Maximum Tolerated Dose or Recommended Phase 2 dose is determined following the evaluation of MDX2004 safety including the incidences of dose limiting toxicities (DLTs), MDX2004 anti-tumor activity, and MDX2004 pharmacokinetics/pharmacodynamics.

    Time frame: 28 days

  3. Part B, C, and D: Objective response rate of MDX2004

    Objective response rate is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

Secondary outcomes

  1. All Study Parts: Measure of terminal half-life (t1/2) of MDX2004

    Characterize pharmacokinetic (PK) parameter t1/2 after intravenous infusion of MDX2004.

    Time frame: 6 months

  2. All Study Parts: Measure of area under the serum concentration-time curve (AUC) of MDX2004

    Characterize pharmacokinetic (PK) parameter AUC after intravenous infusion of MDX2004

    Time frame: 6 months

  3. All Study Parts: Measure of time to maximum concentration (Tmax) of MDX2004

    Characterize pharmacokinetic (PK) parameter Tmax after intravenous infusion of MDX2004

    Time frame: 6 months

  4. All Study Parts: Measure of maximum serum concentration (Cmax) of MDX2004

    Characterize pharmacokinetic (PK) parameter Cmax after intravenous infusion of MDX2004

    Time frame: 6 months

  5. All Study Parts: Measure of volume of distribution (Vd) of MDX2004

    Characterize pharmacokinetic (PK) parameter Vd after intravenous infusion of MDX2004.

    Time frame: 6 months

  6. All Study Parts: Measure of system clearance of MDX2004

    Characterize pharmacokinetic (PK) parameter of system clearance after intravenous infusion of MDX2004.

    Time frame: 6 months

  7. All Study Parts: Evaluation of MDX2004 immunogenicity

    The presence and persistence of anti-MDX2004 antibodies.

    Time frame: 6 months

  8. All Study Parts: Pharmacodynamic characterization of MDX2004

    Changes in T cell phenotypes with MDX2004 administration within the tumor microenvironment (TME) and in blood

    Time frame: 6 months

  9. All Study Parts: Duration of Response (DoR)

    Time from first Complete Response (CR) / Partial Response (PR) to the date of progressive disease (PD) or death, whichever occurs first.

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

  10. All Study Parts: Time to Response

    The time from first dose to first documentation of response (CR or PR).

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

  11. All Study Parts: Disease Control Rate (DCR)

    The proportion of evaluable participants with stable disease (SD) or a best overall response of CR or PR.

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

  12. All Study Parts: Progression Free Survival (PFS)

    The time from the first dose of MDX2004 until the date of disease progression (PD) or death (any cause), whichever occurs first.

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

07

Study locations

6 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jun 2031, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Aug 7, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Jun 30, 2031
CompletionEst.
Jun 30, 2031
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07110584
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Oct 1, 2025
Primary completion
Jun 30, 2031 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Mar 5, 2026

Study contacts

ModeX Therapeutics, An OPKO Health Company
Contact
info@modextx.com
+1 857-233-9936

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion